Carbon monoxide diffusing capacity: a reliable indicator of bleomycin-induced pulmonary toxicity

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Germ-cell tumors are a significant cancer type.
• Chemotherapy regimens like cisplatin, vinblastine, and bleomycin are standard treatments.
• Pulmonary toxicity is a known but not fully understood side effect of chemotherapy.

Purpose of the Study:

• To assess pulmonary function in patients with germ-cell tumors undergoing chemotherapy.
• To investigate subclinical pulmonary toxicity induced by cisplatin, vinblastine, and bleomycin.
• To determine the correlation between bleomycin dosage and pulmonary function changes.

Main Methods:

• Seventy-seven untreated germ-cell tumor patients received 6 courses of cisplatin, vinblastine, and bleomycin.
• Pulmonary function tests, including carbon monoxide diffusion capacity (DLCO) and flow volume loops, were conducted before, during, and after treatment.
• DLCO was corrected for hemoglobin concentration.

Main Results:

• A significant 35% decrease in corrected DLCO was observed in 15 of 18 evaluable patients, despite no clinical or radiological signs of lung toxicity.
• This decrease in DLCO was reversible and correlated with increasing bleomycin dosage (r = 0.63).
• Flow volume relationships showed a non-significant, reversible decrease attributed to treatment strain.

Conclusions:

• Bleomycin-containing chemotherapy causes significant, subclinical pulmonary toxicity, evidenced by decreased DLCO.
• The observed pulmonary toxicity is directly related to the cumulative dose of bleomycin.
• Regular pulmonary function monitoring is crucial for patients receiving bleomycin to detect early signs of lung damage.